This November, HCS Pharma, a pioneer in cell modelling technologies, is joining the global “Movember” initiative to raise awareness and support for prostate cancer research. As a key player in the health sector, we are proud to be taking part in Movember. We firmly believe in the importance of awareness Read more…
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…
Julien Cicero, with whom we are collaborating about the study of breast cancer metastasis mechanisms, was proud to present his PhD work during the last EACR conference. It was held in Torino (Italy) last month, during which Julien could discuss with cancer researchers from all around the world. His poster Read more…
Chez HCS Pharma, nous sommes ravis de partager avec vous les avancées significatives que nous avons réalisées dans nos projets de recherche et développement. Avant de commencer, nous tenons à remercier “La Gazette du Laboratoire” pour leur soutien continu et leur couverture détaillée de nos efforts. Notre entreprise, basée à Read more…
Last week, we had the pleasure to participate in the conference about Alternatives to Animal Experimentation which was held last week in Biocitech park, Romainville, France. It was organized by Adebiotech think tank, and gathered researchers from private companies and academia, and also people from organizations like FC3R and PETA Read more…
Metastasis is the leading cause of death in many cancers. Metastases are particularly harmful when they affect vital organs such as the brain or liver, severely compromising the patient’s quality of life and leading to death. The difficulties of studying metastases in animal models (time, cost, ethical issues) have meant Read more…
The Building Biology in 3D symposium of the Society for Laboratory Automation and Screening (SLAS) took place in Cambridge, United Kingdom, on March 20th and 21th 2023. This congress was the opportunity to discover the dynamic scientific environment of Cambridge. Because this event was focusing on 3D cell culture, most Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
Welcome to HCS Pharma series of webinars and please register for free to the ones you want to attend. You will receive the specific Zoom link within a week prior the event.You will learn more about BIOMIMESYS®, an amazing and disruptive technology that reproduces all aspects of the microenvironment (matrix Read more…
Why is testing important? One million cases of colon cancer are diagnosed each year around the world. Colorectal cancer develops slowly. The tumor, called polyp, appears on the inner wall of the colon and rectum. The evolution of a polyp into cancer can last about ten years. The test can Read more…
We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…
2.2 million cases of breast cancer were identified in 2020 by the WHO. This cancer is the first cause of cancer in women. It develops in the glandular lobes or milk ducts. Five subtypes of breast cancer have been defined but their origin is not yet determined. The heterogeneity of Read more…
After obtaining this Master’s degree in Biology and Health Science at Lille University in 2022, Nathan Laneret has just begun a PhD thesis under the supervision of Pr. RA Toillon and Dr. Nathalie Maubon thanks to ANRT fundings (CIFRE). Through this collaboration between the Cellular Plasticity and Cancer team from Canther Lab Read more…
BIOMIMESYS® is a patented 3D matrix reproducing the physicochemical properties of the extracellular matrix (ECM), different from classical hydrogels used for 3D cell culture. It is composed of native ECM components: Hyaluronic Acid (HA) combined with collagens, adhesion peptides… in the form of a unique hydroscaffold, i.e. exhibiting a dual Read more…
Thomas Meynard, PhD student in OncoLille (under the supervision of Vincent Senez and Isabelle Van Seuningen) in collaboration with HCS Pharma too, presented a poster showing that it is possible to include BIOMIMESYS® in a microfluidic chip to co-culture Cancer-Associated fibroblasts and cancerous cells, with the aim to increase the Read more…
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of Read more…
Nous avons eu le plaisir d’être invités par notre distributeur Dutscher, et en particulier par Romain Guegan, à présenter lors de la journée Necker-Imagine organisée à l’INEM (Institut Necker Enfants Malades) le 3 novembre dernier. Elodie a eu l’occasion de présenter aux chercheurs présents notre technologie BIOMIMESYS® pour une culture Read more…
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
Our project director Elodie is participating to EUSAAT congress in Linz (Austria) this week, the European Congress on Alternatives to Animal Testing. She will have the pleasure to present our work aiming at bridging the gap between in vivo and in vitro situations by taking into account the extracellular matrix Read more…
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon je travaille au laboratoire Canther dans l’institut OncoLille sur le cancer du sein et plus Read more…
